FORM PTO-1449 (Modified)

Approved for use through 10/31/2002

US DEPARTMENT OF COMMERCE

US Patent and Trademark Office

Docket No. 50623.308

Applicant

Application No. 10/718,278

INFORMATION DISCLOSURE CITATION

in an Application
(Use several sheets if necessary)

Syed F.A. Hossainy et al.

Filing Date
November 19, 2003

Group Art Unit
Unknown

	<del></del>		ILO DATE	November 19, 200	<u> </u>	Olli	CHOWII	
S. S.			U.S. PATENT DOCUMENTS		1			
NTB all mer Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate	
	A1	4,329,383	5/11/82	Joh	428	36	7/21/80	
	A2	4,733,665	3/29/88	Palmaz	128	343	11/7/85	
	A3	4,800,882	1/31/89	Gianturco	128	343	3/13/87	
	A4	4,882,168	11/21/89	Casey et al.	424	468	9/5/86	
****	A5	4,886,062	12/12/89	Wiktor	128	343	10/19/87	
****	A6	4,941,870	7/17/90	Okada et al.	600	36	12/30/88	
	A7	4,977,901	12/18/90	Ofstead	128	772	4/6/90	
	A8	5,112,457	5/12/92	Marchant	204	165	7/23/90	
	A9	5,165,919	11/24/92	Sasaki et al.	424	488	9/26/90	
	A10	5,272,012	12/21/93	Opolski	428	423.1	1/29/92	
	A11	5,292,516	3/8/94	Viegas et al.	424	423	11/8/91	
	A12	5,298,260	3/29/94	Viegas et al.	424	486	6/9/92	
	A13	5,300,295	4/5/94	Viegas et al.	424	427	9/13/91	
	A14	5,306,501	4/26/94	Viegas et al.	424	423	11/8/91	
	A15	5,328,471	7/12/94	Slepian	604	101	8/4/93	
	A16	5,330,768	7/19/94	Park et al.	424	501	7/5/91	
	A17	5,380,299	1/10/95	Fearnot et al.	604	265	8/30/93	
	A18	5,417,981	5/23/95	Endo et al.	424	486	4/28/93	
	A19	5,447,724	9/5/95	Helmus et al.	424	426	11/15/93	
	A20	5,455,040	10/3/95	Marchant	424	426	11/19/92	
	A21	5,462,990	10/31/95	Hubbell et al.	525	54.1	10/5/93	
	A22	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93	
	A23	5,569,463	10/29/96	Helmus et al.	424	426	6/7/95	
	A24	5,578,073	11/26/96	Haimovich et al.	623	1	9/16/94	
	A25	5,605,696	2/25/97	Eury et al.	424	423	3/30/95	
	A26	5,609,629	3/11/97	Fearnot et al.	623	1	6/7/95	

	A27	5,624,411	4/29/97	Tuch	604	265	6/7/95
·	A28	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
. <u>.</u>	A29	5,649,977	7/22/97	Campbell	623	1	9/22/94
	A30	5,658,995	8/19/97	Kohn et al.	525	432	11/27/95
	A31	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
	A32	5,670,558	9/10/97	Onishi et al.	523	112	7/6/95
	A33	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
	A34	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
	A35	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
	A36	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A37	5,735,897	4/7/98	Buirge	623	12	1/2/97
	A38	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A39	5,776,184	7/7/98	Tuch	623	1	10/9/96
	A40	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
	A41	5,800,392	9/1/98	Racchini	604	96	5/8/96
	A42	5,820,917	10/13/98	Tuch	427	2.1	6/7/95
	A43	5,824,048	10/20/98	Tuch	623	1	10/9/96
	A44	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
	A45	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
	A46	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
	A47	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
	A48	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97
	A49	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
	A50	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A51	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A52	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
	A53	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A54	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
	A55	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A56	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
	A57	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
	A58	5,980,928	11/9/99	Terry	424	427	7/29/97

			,			
A59	5,980,972	11/9/99	Ding	427	2.24	9/22/97
A60	5,997,517	12/7/99	Whitbourne ·	604	265	1/27/97
A61	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
A62	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
A63	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
A64	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
A65	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
A66	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
A67	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
A68	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
A69	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
A70	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
A71	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
A72	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
A73	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
A74	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
A75	6,113,629	9/5/00	Ken	623	1.1	5/1/98
A76	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
A77	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
 A78	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
A79	6,129,761	10/10/00	Hubbell	623	11	6/7/95
A80	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
A81	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
A82	6,203,551	3/20/01	Wu	606	108	10/4/99
A83	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
A84	6,240,616	6/5/01	Yan	29	527.2	4/15/97
A85	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
A86	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
A87	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
A88	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
A89	6,283,947	9/4/01	Mirzaee	604	264	7/13/99

	A90	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
	A91	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	A92	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
	A93	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	A94	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
	A95	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
	A96	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
	A97	6,346,110	2/12/02	Wu	606	108	1/3/01
-	A98	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
	A99	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A100	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
	A101	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
	A102	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
	A103	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A104	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
	A105	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
	A106	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
	A107	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A108	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A109	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A110	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A111	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A112	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
	A113	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00
	A114	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
	A115	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
	A116	6,572,644	6/3/03	Moein	623	1.11	6/27/01
<del></del>	A117	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
	A118	6,585,926	7/1/03	Mirzaee	264	400	8/31/00

SanFrancisco/119649\_L REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/

	A119	6,605,154	8/12/03	Villareal	118	500	5/3	1/01
		U.S. PATE	NT APPLICAT	ION PUBLICATION DOCU	MENTS			
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	_	Date if priate
	A120	2001/0018469	8/30/01	Chen et al.	523	121	12/2	8/00
	A121	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/2	1/01
	A122	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/1	9/00
	A123	2002/0091433	7/11/02	Ding et al.	623	1.2	12/1	7/01
	A124	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	1/01
	A125	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30	0/02
	A126	2003/0099712	5/29/03	Jayaraman	424	486	11/2	6/01
			FOREIGN PA	ATENT DOCUMENTS	·	· ·		
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Trans Yes	lation No
	B1	EP 0 301 856	2/1/89	European				
***************************************	B2	EP 0 514 406	11/25/92	European				
	В3	EP 0 604 022	6/29/94	European				
	B4	EP 0 623 354	11/9/94	European			•	
	B5	EP 0 665 023	8/2/95	European				
	В6	EP 0 701 802	3/20/96	European				
	B7	EP 0 716 836	6/19/96	European				
	B8	EP 0 809 999	12/3/97	European				
	В9	EP 0 832 655	4/1/98	European				
	B10	EP 0 850 651	7/1/98	European			.=.	
	B11	EP 0 879 595	11/25/98	European				
	B12	EP 0 910 584	4/28/99	European				
	B13	EP 0 923 953	6/23/99	European				
	B14	EP 0 953 320	11/3/99	European				
	B15	EP 0 970 711	1/12/00	European				
	B16	EP 0 982 041	3/1/00	European				
	B17	EP 1 273 314	1/8/03	European				
	B18	2001-190687	7/17/01	Japan (Abstract)			Х	
	B19	WO 91/12846	9/5/91	PCT				
	B20	WO 95/10989	4/27/95	PCT				

			<u> </u>		 
B21	WO 96/40174	12/19/96	PCT		
B22	WO 97/10011	3/20/97	PCT		
B23	WO 97/45105	12/4/97	PCT		
B24	WO 97/46590	12/11/97	PCT		
B25	WO 98/17331	4/30/98	PCT		
B26	WO 98/36784	8/27/98	PCT		
B27	WO 99/01118	1/14/99	PCT		
B28	WO 99/38546	8/5/99	PCT		
B29	WO 99/63981	12/16/99	PCT		
B30	WO 00/02599	1/20/00	PCT		
B31	WO 00/12147	3/9/00	PCT		
B32	WO 00/18446	4/6/00	PCT	_	
B33	WO 00/64506	11/2/00	PCT		
B34	WO 01/01890	1/11/01	PCT		
B35	WO 01/15751	3/8/01	PCT		
B36	WO 01/17577	3/15/01	PCT		
B37	WO 01/45763	6/28/01	PCT		
B38	WO 01/49338	7/12/01	PCT		
B39	WO 01/74414	10/11/01	PCT		
B40	WO 02/03890	1/17/02	PCT		
B41	WO 02/026162	4/4/02	PCT		
B42	WO 02/34311	5/2/02	PCT		
B43	WO 02/056790	7/25/02	PCT		
B44	WO 03/000308	1/3/03	PCT		
B45	WO 03/022323	3/20/03	PCT		
B46	WO 03/028780	4/10/03	PCT		
B47	WO 03/037223	5/8/03	PCT		
B48	WO 03/039612	5/15/03	PCT		
	OTHER DO	CUMENTS (Incl	uding Author, Title, Date, Pertinent P	ages, etc.)	 
C1			he Dream Stent, Clinica 710:15 (J ht?req=1061848202959, printed 8/		
C2			complications by 30%, Clinica 73: tt?req=1061847871753, printed 8/		

•		
·	СЗ	Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
	C4	Anonymous, Stenting continues to dominate cardiology, Clinica 720:22 (Sept. 2, 1996), <a href="http://www.dialogweb.com/cgi/document?req=1061848017752">http://www.dialogweb.com/cgi/document?req=1061848017752</a> , printed 8/25/03 (2 pages).
	C5	Aoyagi et al., Preparation of cross-linked aliphatic polyester and application to thermo-responsive material, Journal of Controlled Release 32:87-96 (1994).
	C6	Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).
	C7	Barbucci et al., Coating of commercially available materials with a new heparinizable material, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
	C8	Chung et al., Inner core segment design for drug delivery control of thermo-responsive polymeric micelles, Journal of Controlled Release 65:93-103 (2000).
	C9	Dev et al., Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
l	C10	Dichek et al., Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells, Circ. 80(5):1347-1353 (Nov. 1989).
	C11	Eigler et al., Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994).
	C12	Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sept. 1991).
	C13	Herdeg et al., Antiproliferative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Cardiol. 3:197-199 (1998).
•	C14	Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).
	C15	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).
	C16	Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
	C17	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
	C18	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
	C19	Matsumaru et al., <i>Embolic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C20	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C21	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C22	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C23	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).
	C24	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C25	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).

EXAMINER		/Charlesworth Rae/	DATE CONSIDERED 01/03/2009				
	C30		ion of physical entrapment and chemical conjugation of adriamycin in sign for in vivo delivery to a solid tumor, Journal of Controlled Release				
	C29 Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Art</i> Cardiovasc. Med. 3(5):163-170 (1993).						
	C28	van Beusekom et al., Coronary	stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).				
	C27 Shigeno, Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor, C Abstract 125:212307 (1996).						
	C26	Peng et al., Role of polymers in 694 (1996).	improving the results of stenting in coronary arteries, Biomaterials 17:685				

Include copy of this form with next communication to applicant.